Cardio Diagnostics Holdings Inc (CDIO) - Total Liabilities
Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has total liabilities worth $793.06K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cardio Diagnostics Holdings Inc - Total Liabilities Trend (2020–2025)
This chart illustrates how Cardio Diagnostics Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Cardio Diagnostics Holdings Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Cardio Diagnostics Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trainers House Oyj
HE:TRH1V
|
Finland | €2.32 Million |
|
Strike Resources Ltd
AU:SRK
|
Australia | AU$812.49K |
|
BetterLife Pharma Inc
F:NPAU
|
Germany | €6.04 Million |
|
Noronex Ltd
AU:NRX
|
Australia | AU$1.04 Million |
|
Adalta Ltd
AU:1AD
|
Australia | AU$2.07 Million |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
USA | $804.27K |
|
SVP GLOBAL TEXTILES LIMITED
NSE:SVPGLOB
|
India | Rs33.27 Billion |
|
5E ADVANCED MATERIALS CDI
F:J9I0
|
Germany | €6.99 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Cardio Diagnostics Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cardio Diagnostics Holdings Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cardio Diagnostics Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual total liabilities of Cardio Diagnostics Holdings Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $793.06K | -25.01% |
| 2024-12-31 | $1.06 Million | -29.70% |
| 2023-12-31 | $1.50 Million | -22.77% |
| 2022-12-31 | $1.95 Million | +5648.18% |
| 2021-12-31 | $33.88K | -91.22% |
| 2020-12-31 | $386.01K | -- |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more